Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

WHO petition against proposals to reschedule ketamine
Ketamine
"Restrictions on its use would have a significant and negative impact on animal welfare on a global scale."

Move would prohibit ketamine's use in both human and veterinary medicine

The World Health Organisation (WHO) have launched a petition against proposals to reschedule ketamine as a controlled substance with international scope.

Several countries are lobbying to have the Commission on Narcotic Drugs re-schedule the drug. The move would effectively prohibit ketamine's use in both human and veterinary medicine.

WHO is petitioning against the proposal as they believe it will significantly undermine the ability to provide cost effective anaesthesia and analgesia in various parts of the world.

If it does go ahead, every aspect of ketamine production would have a mandated compliance and regulatory protocol attached to it. 
This would reduce the supply - because increased costs would cause some manufactures to leave the market.  It would also result in a restriction of its use to essentially experimental settings, as it would be scheduled with drugs such as LSD.

The WSAVA are concerned that, should the motion to reschedule the drug move forward, it would result in additional restrictions on access to it. 

"It could effectively remove it from veterinary use," said a spokesperson.

In a statement defining their position, the WSAVA Global Pain Council said: "Access to anesthetic and analgesic drugs is imperative for the mitigation of animal suffering and the WSAVA's Global Pain Council was created to address inequalities in both education and access to analgesic/anesthetic modalities in differing regions of the world.  

"In some regions, ketamine is the only analgesic/anesthetic agent available to the veterinary profession and is essential to enable veterinarians to perform their day-to-day activities in an ethical and humane manner.  

Restrictions on its use would have a significant and negative impact on animal welfare on a global scale.  As such, the WSAVA and its Global Pain Council lend their support to the Ketamine Fact Sheet and efforts to halt any initiatives that seek to have it rescheduled."

The WSAVA are now calling for vets to support them by letting the secretariat know of their opposition to the proposal.

"We will add you voice to the growing global small animal veterinary voice opposing this initiative," they add.

For more information on ketamine visit www.wsava.org

Image (C) Coaster420

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.